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There is a critical need to deconvolute the heterogeneity displayed by the minor salivary
glands of primary Sjögren’s syndrome (pSS) patients. This is challenging primarily
because the disease etiology remains unknown. The hypothesis includes that initial
events in the disease pathogenesis target the salivary glands, thereby triggering the
development of focal infiltrates (≥50 mononuclear cells) and finally germinal center-like
structures. However, the proportion of key mononuclear immune cells residing at these
sites, in combination with the overall ratio of morphometric tissue atrophy and adipose
infiltration within the minor salivary glands (MSG) parenchyma at distinct phases of
inflammatory disease establishment and progression have not been quantified in detail.
In this cross-sectional study, we intended to address this problem by stratifying 85
patients into mild (S1), moderate (S2), and severe (S3) stages using the Inflammatory
severity index. We found that mild (<3%) and marked (≥3%) levels of atrophy were
accompanied by the respective levels of adipose infiltration in the non-SS sicca controls
(p <0.01), but not in pSS patients. The percentage of adipose infiltration significantly
correlated with the age of patients (r = 0.458, p <0.0001) and controls (r = 0.515,
p <0.0001). The CD4+ T helper cell incidence was reduced in the focal infiltrates of the
MSG of S2 patients compared to S1 (p <0.01), and in S2 compared to S1 and S3
combined (p <0.05). CD20+ B cells increased from S1 to S3 (p <0.01) and S2 to S3
(p <0.01), meanwhile CD138+ plasma cells diminished in S3 patients compared to both
S1 and S2 groups combined (p <0.01). The proportion of patients with anti-Ro/SSA+,
anti-La/SSB+, and RF+ increased over the course of inflammatory disease progression
and they were significantly more common in the S3 group relative to S1 (p <0.05). On
the other hand, S2 patients measured a higher mean salivary flow relative to S1 and S3
patients combined (p <0.05). Our results demonstrate how the proposed Inflammatory
severity index stratification revealed pathological cell and tissue-associated aberrations
in the salivary component over the course of inflammatory progression, and theirorg July 2021 | Volume 12 | Article 7015811
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Frontiers in Immunology | www.frontiersin.correlations to clinical outcomes. This could be directly transferred to the optimization of
available diagnostic strategies applied for pSS patients.Keywords: primary Sjögren’s syndrome, patient stratification, inflammatory severity index, minor salivary glands,
adipose tissue, T cells, B cells, antigen-presenting cellsINTRODUCTION
Primary Sjögren’s syndrome (pSS) is a heterogenous autoimmune
disease characterized by chronic inflammation that is manifested by
mononuclear cell infiltration in the exocrine glands, namely the
salivary and lacrimal glands. The minor salivary gland (MSG) tissue
can be diagnostically examined by using the focus score (FS) which
describes thenumberof cell infiltrates of at least 50mononuclear cells
within 4 mm2 (i.e., a focal infiltrate). Higher FS has been correlated
with severe disease (1, 2) and associated with the occurrence of well-
organized focal infiltrates closely resembling the germinal centers of
secondary lymphoid organs with a light and dark zone (3). Due to
their ectopic location in the salivary glands, such infiltrates are termed
germinal-center like structures (GC), and have been reported in 25–
30%of pSS patients (4, 5). The presence ofGC in the diagnostic labial
salivary gland have frequently been associated with antibody and
immunoglobulin production (3) and a greater risk of lymphoma
development (5, 6). Nevertheless, more studies are needed for a valid
evaluation of their prognostic role (7), and hence, theGC+biopsies of
pSS patients do require special attention.
The heterogeneity in pSS also reflects on a histopathological
level, where morphological features apart from the inflammatory
lesions, such as salivary gland atrophy and adipose infiltration yet
have not gained as much attention and diagnostic value (8). This
could partially be ascribed to biological aging as has been found to
correlate positively to the grade of atrophy or adipose tissue in the
target organofpSSpatients for a long time (9–12).At the same time,
pro-inflammatory mediators have been linked to atrophy and
adipose infiltration in the glandular tissue (13, 14), and few studies
have compared these respective tissue types morphologically by
utilizing digital quantification techniques in a larger sample size.
Primarily, the focal infiltrations represent the hallmark feature in
MSG biopsies of pSS patients, and these areas mainly comprise T
and B lymphocytes and antigen-presenting cells (APCs).
Nevertheless, the distribution of cell types within the focal
infiltrates at distinct stages of inflammatory progression has been
described by a few published studies (15), and a methodological
concern lies in the patient stratification, where the GC+ and GC-
patients were not assessed separately.
Herein, we sought to investigate the immunopathological
changes in the MSG of pSS patients by disseminating stages from
themildphase to highly developed lesions. Specifically, we aimed to
create an Inflammatory severity index of disease activity to
subgroup patients, in order to i) morphometrically quantify areas
of atrophy and adipose infiltrations in theMSG of pSS patients and
investigate a potential relationship between the two tissue types,
and ii) measure the incidence and composition of key immune cell
populations that comprise the focal infiltrates from mild to severeorg 2lesions. The infiltrating cell types analyzed included CD4+ T helper
cells (Th cells), CD8+ T cytotoxic cells (Tc cells), FoxP3+ T
regulatory cells (FoxP3 Tregs), CD74+ (class II MHC expressing)
APCs, CD68+ macrophages, CD20+ B cells, and CD138+
plasma cells.MATERIAL AND METHODS
Study Population and Design
This cross-sectional study included MSG biopsies from 85 pSS
patients and 47 age-and gender-matched non-SS sicca tissue
controls. As part of the diagnostic procedure the biopsies were
obtained between the years 1989 and 2009 at the Department of
Otorhinolaryngology, Haukeland University Hospital, Bergen. All
patients fulfilled the American–European classification criteria
(AECG) (16), and after a post-hoc re-classification 70 patients
(80%) additionally fulfilled the revised 2016 ACR/EULAR
criteria (17).
Medical records and subject charts were obtained from the
Department of Rheumatology at Haukeland University Hospital
and were retrospectively assessed for sicca manifestations, alongside
laboratory and histopathological parameters. Sicca manifestations
were tested using Schirmer’s test and sialometry, while serology
findings included seropositivity for the following antibodies:
antinuclear antibody (ANA), anti-Ro/SSA, anti-La/SSB, and
rheumatoid factor (RF). Additional histopathological features
included FS and GC in pSS patients at the time of diagnosis.
Patients lacking biopsy data were excluded from the analysis.
Moreover, since assessments of FS and GC are semi-quantitative
methods where the histopathological tissue architecture might differ
on multiple sections taken from the same gland, a re-evaluation of
the FS and GC was conducted on MSG tissue from all pSS patients
in order to eliminate potential discrepancies. This was performed on
hematoxylin–eosin-stained sections in accordance with our
previous laboratory examinations of such structures (18).
Patient stratification was carried out by stratifying the pSS
patients into three distinct groups, where each group represented
a disease stage according to the degree of inflammation in their
MSG using the Inflammatory severity index. Patients with mild
lesions (FS ≤1) were included in the first stage (S1), patients with
moderate lesions (FS ≥2) were included in the second stage (S2),
while patients displaying severe lesions and GC in the MSG tissue
(FS ≥2 and GC+) were classified in the third stage (S3). Informed
consent was obtained from all subjects included and the study was
approved by the Regional committee of Ethics, Western-Norway
(2009/686). The clinical and histopathological characteristics of pSS
patients and non-SS controls are summarized in Table 1.July 2021 | Volume 12 | Article 701581
TABLE 1 | Mean/median values and number (%) of all patients and non-SS control subjects in the total sample size positive for the clinical and histopathological characteristics.
Statistical significance (p-value) Non-SS sicca subjects
Statistical comparison
, n = 17 (%) S1 vs. S2 S2 vs. S3 S1 vs. S3 Total, n = 47 (%)
6/17 (94.1) 43/47(91.5)
9.9 ± 2.68 54.7 ± 1.41
3/15 (86.7) 0.993 a 0.145 b 0.106 b 7/47(14.9)
3/17 (76.5) 0.310 a 0.228 a 0.029 a 0/46 (0)
/17 (47.1) 0.003 a 0.938 a 0.014 b 0/46 (0)
/17 (23.5) 0.547 b 0.212 b 0.019 b 2/47 (4.3)
.24 ± 0.66 0.21 ± 0.06
[2.50–5.50] 0.00 [0.00–0.50]
7/17 (100) 0 (0)
.68 ± 0.50 0.225 c 0.653 c 0.479 c 4.33 ± 0.68
3.11 [1.50–6.82]
0/17 (58.8) 0.632 a 0.975 a 0.645 a 25/47 (53.2)
.96 ± 3.06 0.949 c 0.199 c 0.145 c 5.60 ± 1.35
[0.40–10.44] 1.78 [0.57–7.22]
/17 (29.4) 0.976 a 0.116 a 0.078 a 19/47 (40.4)
.31 ± 0.59 0.047 c 0.012 c 0.070 c 1.48 ± 0.17
[0.00–1.20] 1.25 [0.85–1.80]
1/13 (84.6) 0.373 a 0.022 a 0.102 b 26/40 (65.0)
1.2 ± 2.90 0.067 c 0.989 c 0.143 c 4.28 ± 0.66
0 [2.75–16] 3.00 [2.00–6.00]
0/17 (58.8) 0.072 a 0.767 a 0.053 a 33/43 (76.7)
atoid arthritis; FS, focus score; GC, germinal center-like structures; UWSF, unstimulated whole saliva
edian [IQR] was used when the data followed a non-normal distribution.
at least 50 mononuclear cells. When FS <1 the numeric value was set to 0.5.




































Total, n = 85 (%) S1, n = 44 (%) S2, n = 24 (%) S3
Female 82/85 (96.5) 42/44 (95.5) 24/24 (100) 1
Mean age (years) 52.4 ± 1.22 52.8 ± 1.63 53.5 ± 2.51 4
ANA+* 52/79 (65.8) 25/41 (61.0) 14/23 (60.9) 1
Anti-Ro/SSA+* 47/85 (55.3) 20/44 (45.5) 14/24 (58.3) 1
Anti-La/SSB+* 25/85 (29.4) 6/44 (13.6) 11/24 (45.8) 8
RF+* 7/85 (8.2) 1/44 (2.27) 2/24 (8.33) 4
Mean FS ** 2.14 ± 0.22 0.75 ± 0.06 3.21 ± 0.29 4
Median FS ** 1.00 [1.00–3.00] 1.00 [0.50–1.00] 3.00 [2.00–4.00] 3.0
GC+ 17/85 (20.0) 0 (0) 0 (0) 1
Mean atrophy*** 3.77 ± 0.26 3.56 ± 0.38 4.22 ± 0.51 3
Median atrophy*** 3.22 [2.08–5.15] 3.07 [1.80–4.86]
Marked atrophy*** 47/85 (55.3) 23/44 (52.3) 14/24 (58.3) 1
Mean adipose tissue*** 8.82 ± 1.31 9.49 ± 1.80 8.92 ± 2.51 6
Median adipose tissue*** 2.81 [0.75–13.03] 3.52 [0.71–13.59] 3.72 [1.02–12.33] 1.36
Marked adipose tissue*** 42/85 (49.4) 24/44 (54.5) 13/24 (54.2) 5
Mean UWSF**** 2.00 ± 0.27 1.70 ± 0.31 2.98 ± 0.62 1
Median UWSF**** 1.20 [0.45–2.35] 1.30 [0.30–2.00] 2.00 [1.00–4.00] 0.7
Decreased UWSF (hyposalivation)***** 45/77 (58.4) 24/42 (57.1) 10/22 (45.5) 1
Mean Schirmer’s test****** 13.37 ± 1.30 16.0 ± 1.94 10.1 ± 1.92 1
Median Schirmer’s test****** 10 [3.50–21.0] 11.25 [4.88–23.88] 7.25 [2.38–18.63] 5.5




Significant values (p <0.05) underlined.
S1, Mild stage; S2, Moderate stage; and S3, Severe stage along the Inflammatory severity index; ANA, Antinuclear antibody; RF, Rheum
flow. Mean values presented with standard error of mean (SEM) when data was normally distributed, i.e. Shapiro–Wilk test p >0.05. M
*ANA, anti-Ro/SSA, and anti-La/SSB autoantibodies were detected using ELISA. RF was detected using Waaler’s test.
**A re-evaluation of the FS was carried out in all MSG. Values are the mean of the number of focal infiltrates/4 mm2 area comprising o
***The morphometric areas of atrophy and adipose tissue were quantified as a percentage of the total MSG parenchymal area, where
not shown).
****Values are in ml/15 min. Eight subjects missing.
*****A salivary flow of ≤1.5 ml/15 min denotes a positive sialometry test.
******Values are in mm/5 min. Mean of lacrimal flow from both eyes.
*******A lacrimal flow of ≤ 5mm/5 min in at least one eye denotes a positive Schirmer’s test.0
0
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Bharaj et al. Immune Cell Alterations in pSSHistomorphometric Analysis of Atrophy
and Adipose Tissue
Hematoxylin–eosin-stained MSG sections were digitally scanned
by the Hamamatsu NanoZoomer-XR digital whole slide scanner
and converted into digital images available on Aperio
ImageScope computer software (v12.4.3.5008; Leica
Microsystems GmbH, Wetzlar, Germany). Atrophic and
adipose areas within the parenchyma of the MSG were
separately identified, morphometrically compartmentalized on
the magnification of ×4 using the Pen tool in Aperio ImageScope
(Figure 1), and finally divided by the total parenchymal area,
giving the respective percentages of total atrophy and adipose
tissue present in each biopsy. The MSG biopsies with mild (<3%)
and marked levels (≥3%) of atrophy or adipose tissue were
segregated due to a positively skewed distribution and to allow
for a systemization of the MSG upon the grade of occupied
tissues. All measurements were assessed blindly by two
investigators (TKB, KS).
The analysis was conducted using four inclusion criteria. Firstly,
structures located within atrophic or adipose regions that were
maximum 3.5 μm² in size, such as horizontally cut capillaries or
small ducts, were included in the measurements, while structures
above 3.5 μm² were excluded. Other incompatible structures were
also left out regardless of size. Secondly, only atrophy and adipose
tissue inside the glandular parenchyma were measured. Thus,
stromal tissue consisting of exterior fat, loose connective tissue,
and other structures were not added in the calculation of the MSG
area. Thirdly, the atrophic area comprised of damaged and/or
irregular glandular tissue and densely packed connective tissue.
Hence, loose connective tissue in the interlobular septa was not
included, and focal infiltrates were left out as inflammatory cells
covered the underlying tissue. Fourthly, adipose areas with at least
three co-localized adipocyteswere included in the analysis, whereas
single and double adipocytes were excluded. Independent regionsFrontiers in Immunology | www.frontiersin.org 4entirely or predominantly covered by adipose tissuewere precluded
from the analysis, unless they displayed structures attributable to
MSG parenchyma, such as acinar cells or glandular ducts.
Immunohistochemistry
Single Staining
Formalin-fixed paraffin embedded tissue ofMSG frompSS patients
were cut into 4 μm thick sections using a microtome (Leica
Instruments GmbH, Nussloch, Germany). Next, the sections were
placed on SuperFrost® Plus microscope slides (Fisher Scientific,
Waltham,MA,USA) and incubated overnight at 56°C.A total of 30
pSS patients from the histomorphometric analysis fulfilling the
2017 ACR/EULAR criteria (17) were enrolled in the analysis
(Supplementary Table 1). MSG biopsies of patients with absence
offocal infiltrates (FS=0)werenot included.As someof thebiopsies
from the current pSS patient cohort had been used in previous
works (19, 20) biopsies with insufficient MSG tissue had to be
excluded, especially considering the number of sections that had to
be taken from each patient for the staining procedure. The single
staining technique was performed using mouse-monoclonal anti‐
human antibodies obtained from Agilent (Carpintera, CA, USA)
that targetedCD4 (1:100dilution, clone 4B12),CD8 (1:200dilution,
cloneC8/144B),CD21 (1:100dilution, clone 1F8), andCD68 (1:150
dilution, clone PG-M1). In addition, FoxP3 (1:100 dilution, clone
259D/C7, BD Biosciences Pharmingen, San Diego, CA, United
States), and rabbit-polyclonal antibody detecting human CD74
molecule (1:250 dilution, Atlas Antibodies, Stockholm, Sweden)
were included in the investigation.
The immunohistochemical analysis was carried out using the
Envision FLEX+ kit (K8012, Agilent, Carpintera, CA, USA).
After overnight incubation, sections were deparaffinized in
xylene and rehydrated by serial dilutions of ethanol in distilled
water (100, 96, and 70%). They were subjected to heat-induced
epitope retrieval (HIER) in a microwave for 25 min and blockedA B
FIGURE 1 | Morphometric distinction of atrophy and adipose tissue in one MSG from two patients with pSS. One representative salivary gland from each patient
biopsy, using AperioImage Scope©, are shown. Atrophy and adipose tissue were quantified as a percentage of the total MSG parenchymal area. Parenchymal
atrophy in the MSG biopsy of patient (A) was 9.1% and parenchymal adipose infiltration in patient (B) was 49,4%, where both possessed marked levels. Scale bar = 0.5 mm.July 2021 | Volume 12 | Article 701581
Bharaj et al. Immune Cell Alterations in pSSwith peroxidase for 5 min, followed by a 1:10 dilution of Normal
goat serum (X0907, Agilent, Carpintera, CA, USA) in 3% Bovine
serum albumin (BSA) solution for 20 min. Next, the serum was
removed, and the sections were incubated with the primary
antibody mixed in diluent (K8006, Agilent, Carpinteria, CA,
USA) for 60 min, following EnVision FLEX+ horseradish
peroxidase (HRP)—conjugated secondary antibody for 20 min.
3,3′-diaminobenzidine (DAB, K3468, Agilent, Carpinteria, CA,
USA) was applied on the sections and excessive chromogen was
washed away with distilled water after 10 min. The sections were
then counterstained with hematoxylin (S3301, Agilent,
Carpinteria, CA, USA) for another 10 min, dehydrated via a
graded ethanol series, and finally mounted with Pertex (Histolab
Products AB, Gothenburg, Sweden). Following epitope-retrieval,
all incubations were performed at room temperature, and Tris-
buffered saline (TBS) pH 7.6 was used as a washing buffer
between all steps. For antibodies CD4, CD8, and FoxP3
normal goat serum was replaced by a serum-free Protein block
(X0909, Agilent, Carpintera, CA, USA), and an additional
amplification step where EnVision FLEX+ Mouse Linker was
incubated for 15 min following the primary antibody was added.
Normal goat serum was not used for the CD21 antibody.
Double Staining of CD138 and CD20
Double-staining with mouse-monoclonal antibodies targeting
human CD138 (1:200 dilution, clone MI15, Agilent, Carpintera,
CA, USA) and CD20 (1:3,000 dilution, clone L26, Agilent,
Carpintera, CA, USA) was performed. Here, CD138 was the first
primary antibody incubated for 60 min at room temperature and
developed using DAB similarly to the single-staining-technique
described above. The sections were then treated with Dual
Endogenous Enzyme Block (S2003, Agilent, Carpintera, CA,
USA) for 5 min, and incubated with the second primary antibody
CD20 overnight at 4°C. The following day, sections were stained
with Vulcan Fast Red Chromogen (BiocareMedical, Concord, CA,
USA). The sections were counterstained with hematoxylin for
10 min, dehydrated, and mounted as described above.
Evaluation of Staining
In order to evaluate the staining in a replicable manner, the MSG
sections were converted into digital images accessible on Aperio
ImageScope software as described above. Staining of CD21+
follicular dendritic cells (fDC) was carried out in order to verify the
presenceofCD21+networks centrallywithin theGC in the tissueand
ensure accurate S3 patient stratification with regard to the
Inflammatory severity index. The rest of the antibodies were
included in the staining analysis to assess the percentages of each
immune cell population within the focal infiltrates of MSG tissue.
Focal infiltrates with minimum 50 mononuclear cells located
periductally or perivascularly, in close proximity to normal
parenchyma and not adjacent to acinar atrophy, duct dilation, or
fibrosis were included to avoid bias in the analysis, as is in line with
the revised recommendations of Fisher et al. from 2016 (21). Cells
were identified as positive based on typical morphology and at least
50% of the cell membrane, cytoplasm, or nucleus stained positively.
Independent cell counting was performed manually by two
investigators (TKB, KS) to control for the inter-observer variability.Frontiers in Immunology | www.frontiersin.org 5Positive cells located in fivemanually annotated focal infiltrates were
countedusing theCounterTool on a×40-objectivemagnification for
each MSG. However, in MSG possessing <5 focal infiltrates the
positively stained cell populations in all infiltrates present were
examined. To further minimize discrepancies, the same focal
infiltrates were investigated for every staining performed in each
pSS patient, whenever feasible (Supplementary Table 2). To
exclude differences attributable to the severity of lesions, counting
was expressed as the number of positive cells/total number of
infiltrating mononuclear cells for each focal infiltrate, and the
percentage of each immune cell population was deduced (Table 2).
Statistical Analysis
For the statistical analysis and comparison between groups, Chi-
square and Fisher’s Exact Tests were applied primarily. Differences
inmeanswere investigatedwith Student’s T test and the accuracy of
the results were presented using standard error mean (SEM).
Continuous variables were explored using Shapiro–Wilk test and
considered normally distributed at p >0.05. Mann–Whitney U test
was carried out for non-parametric data and Pearson correlation
test was used to determine the strength and direction of the linear
regression. A p-value <0.05 was considered statistically significant.
Analyses were performed using the IBM SPSS Statistics v. 20.0.0
software and statistical figures were generated using Prism
9 (GraphPad).RESULTS
Inflammatory Disease Severity in the
MSG of pSS Patients Influence Adipose
Tissue Replacement, Hyposalivation,
and Autoantibodies
In this study, atrophic and adipose regions (Figure 1) were
assessed in all control subjects, and in patients who were
classified based on the glandular inflammation grade and
upon the confirmation of GC (Figure 2) into the S1 (n =
44), S2 (n = 24) and S3 (n = 17). The mean glandular atrophy
appeared consistent across all inflammatory severity stages, and
between pSS patients compared to non-SS controls. Adipose
tissue within the glandular parenchyma was 3.2% higher in
MSG of patients compared to non-SS controls, although not
significantly, and indicated a decreasing trend with greater
inflammatory severity. Moreover, the mean age of diagnosis
was 52.4 (± 1.22) for the pSS patients and 54.7 (± 1.41) for the
non-SS sicca subjects, whereupon a positive correlation between
the age and parenchymal adipose infiltration in both the patient
(r = 0.458, p <0.0001) and non-SS sicca controls biopsies (r =
0.515, p <0.0001) was discovered. Conversely, age could not be
associated with atrophy within the pSS patients, nor non-SS
control biopsies. Furthermore, no association was observed
between levels of atrophy and adipose infiltration in the MSG
of the two groups. However, when the Chi-square test was
applied to determine a relationship between mild and marked
levels, it revealed that non-SS subjects with mild atrophy in
their MSG exhibited mild adipose infiltration, while non-SS
individuals with marked atrophy also displayed enhancedJuly 2021 | Volume 12 | Article 701581
Bharaj et al. Immune Cell Alterations in pSSadipose deposition (p <0.01). The reciprocal pattern was not
identified in the pSS patients.
The mean lacrimal flow of both eyes in the patients was measured
and inversely correlated with their age (r = −0.268, p <0.05) and their
focus score (r = −0.240, p <0.05). The percentage of patients with a
positive Schirmer’s test increased with higher disease severity, where
the incidence of patients with a positive test almost doubled in S3
compared to S1. Additionally, hyposalivation (≤1.50 ml/15 min) was
considerably more common in S3 patients relative to those in the S2
group (p <0.05). Of note, patients in S2 measured a higher mean
salivary flow relative to S1 and S3 patients combined (p <0.05).
Relatively to S1, a significantly higher prevalence of patients
in S3 were seropositive for anti-Ro/SSA (p <0.05) and RF
(p <0.05), and the percentage of patients with the respective
autoantibodies increased with higher inflammatory diseaseFrontiers in Immunology | www.frontiersin.org 6severity. Meanwhile, anti-La/SSB positivity was less common in
S1 compared to both S2 (p <0.01) and S3 (p <0.05) (Table 1). No
correlations were observed between the aforementioned clinical
parameters and the immunological patterns examined below
(data not shown).
Lower Numbers of T Cell Subsets
Detected in the Target Organ of pSS
Patients Reflecting High Inflammatory
Disease Severity
Immunohistochemistry was performed to quantify immune cells
in the MSG of patients in the severity stages S1 (n = 11), S2 (n =
9), and S3 (n = 10). Three sub-populations of T cells (CD4+ Th
cells, CD8+ Tc cells, and FoxP3+ Tregs) were investigated. CD4+
Th cells were prominent in all patients from each stage andTABLE 2 | Composition of key immune cells in the focal infiltrates of patients included in the immunohistochemical analysis, expressed as the mean/median percentage
of total infiltrating mononuclear cells.
Type of mononuclear cell pSS patients Statistical significance (p-value)
Inflammatory severity index Statistical comparison
Total, n = 30 (%) S1, n = 11 (%) S2, n = 9 (%) S3, n = 10 (%) S1 vs. S2 S2 vs. S3 S1 vs. S3
Mean CD4+ Th cells 29.6 ± 1.71 33.09 ± 2.29 23.11 ± 2.56 31.50 ± 3.23 0.009 d 0.061 d 0.688 d
Mean CD8+ Tc cells 21.7 ± 1.88 23.73 ± 2.97 21.00 ± 3.19 20.20 ± 3.81 0.541 d 0.876 d 0.470 d
Mean FoxP3+ Tregs 0.70 ± 0.16 0.82 ± 0.26 0.56 ± 0.34 0.70 ± 0.26 0.456 c 0.604 c 0.809 c
Median FoxP3+ Tregs 0.00 [0.00–1.00] 1.00 [0.00–2.00] 0.00 [0.00–1.00] 0.50 [0.00–11.25]
Mean CD74+ APCs 35.7 ± 2.60 32.36 ± 4.31 36.33 ± 4.73 38.70 ± 4.71 0.543 d 0.604 c 0.349 c
Median CD74+ APCs 46.0 [31.75–48.50]
Mean CD68+ macrophages 1.63 ± 0.41 2.00 ± 0.94 1.11 ± 0.56 1.70 ± 0.50 0.370 c 0.356 c 0.756 c
Median CD68+ macrophages 1.00 [0.00–2.25] 1.00 [0.00–2.00] 0.00 [0.00–2.50]
Mean CD20+ B cells 23.5 ± 2.79 16.64 ± 3.16 17.33 ± 2.65 36.50 ± 5.38 0.871 d 0.004 c 0.004 d
Median CD20+ B cells 20.0 [12.00–30.50]
Mean CD138+ plasma cells 12.1 ± 1.91 14.45 ± 3.52 14.67 ± 3.46 7.10 ± 2.50 0.603 c 0.053 c 0.072 c
Median CD138+ plasma cells 8.00 [5.00–19.25] 8.00 [5.00–24.00] 13.0 [7.00–21.50] 4.00 [1.00–13.00]July 2021 | Volume 12 | ArticMann–Whitney U test.
dStudent's T test. Significant values (p <0.05) underlined.
S1, Mild stage; S2, Moderate stage; S3, Severe stage along the Inflammatory severity index; APCs, Antigen-presenting cells. Mean (%) values presented with standard error of mean (SEM)
when data was normally distributed, i.e. Shapiro–Wilk test p >0.05. Median (%) [IQR] was used when the data followed a non-normal distribution.A B
FIGURE 2 | A CD21+ network of follicular DCs in GC in a MSG of a patient with pSS. Staining with CD21 antibody performed in all biopsies to identify a
characteristic fDC-network formed in the light zone of GC. Image (B) is a magnification of (A). Scale bar = 0.5 mm.cle 701581
Bharaj et al. Immune Cell Alterations in pSSespecially numerous in focal infiltrates of the S1 group
(Figures 3A–F). A substantial difference in the number of
positive cells was observed between S1 and S2, where the mean
value of counted cells was 10% higher in S1 patients compared to
S2 (p <0.01). The number of CD4+ Th cells increased from S2 to
S3, although not significantly (Figure 3G). Meanwhile, CD8+ Tc
cells were found mostly in the focal infiltrates but were less
densely packed, and in some patients these cells were frequently
observed within the excretory ducts close to the infiltrates
(Figures 4A–F). The CD8+ cells constituted approximately
20% of the lymphocytic foci in all severity stages, and there
appeared to be a slight decrease with higher inflammatory
severity (Figure 4G). Moreover, the FoxP3+ Tregs were scarce
or absent in the majority of MSG (Figures 5A–F), yet the
incidence of the cells was found to follow a similar trend as
that of the CD4+ Th cells, with the highest mean percentage of
cells detected in S1 and the lowest number observed in S2
patients (Figure 5G).
Increased Infiltration of APCs at the Site of
Inflammation in pSS Patients With Higher
Inflammatory Disease Severity
Overall, the CD74+ expressing APCs represented the most
abundant cell population in the focal infiltrates (Figures 6A–F)
and increased in parallel with greater inflammatory disease
severity, where S3 patients displayed a mean amount of
approximately 40% positive cells (Figure 6G). Additionally,
CD68+ macrophages were mostly found to be scattered and
localized either interstitially or on the periphery of the infiltrates
at the site of inflammation. Focal infiltrates were more enriched
with this subgroup of APCs as compared to the GC (Figures 7A–F).
This observation fits well with the small change in incidence of
CD68+ macrophages discovered with respect to increasing
inflammatory severity, as the highest occurrence rate was
encountered in S1 and the smallest was seen in the S3 group
(Figure 7G). Nevertheless, the total number of APCs occupying the
infiltrates, with macrophages included, was highly elevated in
S3 patients.
Accumulation of CD20+ B Cells in MSGs of
pSS Patients Displaying High Inflammatory
Disease Severity and a Decline in CD138+
Plasma Cells
The CD20+ B cells heavily infiltrated the focal infiltrates of
patients with GC, while the CD138+ plasma cells appeared to
be rather condensed into clusters interstitially. Both cell types
were commonly located in various regions of adipose deposition
(Figures 8A–F). Strikingly, the CD20+ B cells exhibited the
greatest variation in number amongst the three severity stages
and were significantly up-regulated in MSG of S3 patients as
compared to S1 (p <0.01), S2 (p <0.01) and both groups
combined (p <0.01) (Figures 8G). On the other hand, the
frequency of CD138+ plasma cells remained relatively
consistent in both S1 and S2, yet diminished in S3, thereby
giving rise to a considerable difference when comparing S3 with
the S1 and S2 groups collectively (p <0.01) (Figure 8H).Frontiers in Immunology | www.frontiersin.org 7DISCUSSION AND CONCLUSION
The histopathology of salivary glands in pSS is of particular
interest as several clinical, biological, and immunological
aberrations have been directly attributed to changes that occur
in the patients’ glandular tissue (3, 4, 22, 23). At the same time,
only a few published studies have concerned the extent of
atrophy and adipose tissue in the disease target organ,
although both features represent important degenerative
changes where functional acinar cells are damaged or replaced
(8). To the best of our knowledge, we are the first to present data
that mild and marked atrophy levels in the salivary gland
parenchyma of non-SS sicca controls significantly coincided
with the respective levels of adipose infiltration, and that a
similar parallel could not be drawn in the pSS patients
(p <0.01). Common to both groups was a positive correlation
between the age of diagnosis and adipose accumulation in the
salivary glands, as has been demonstrated in patients previously
(11, 24). On the other hand, adipocytes have been reported to
localize inside favourable microenvironments, including
interleukin (IL)-6 and IL-17 rich milieus that associate with
the glandular inflammatory activity in pSS (14, 25). Additionally,
the release of adiponectin by salivary gland epithelial cells could
be in favour of the infiltrating adipocytes (26). Therefore,
multiple biological and pathological mechanisms may
collectively support the proliferation or presence of these cells
within the salivary glands, also considering that a slightly higher
mean adipose accumulation was detected in pSS patients as
compared to non-SS individuals.
In this study, pSS patients with GC generally experienced
reduced mean salivary flow (4, 27), meanwhile, it appears that
salivary secretion largely but not consistently correlated with the
FS (27). Here, we demonstrated a significantly reduced salivary
flow in patients with mild and severe lesions collectively,
compared to patients with moderate lesions. As expected,
seropositivity to ANA, anti-Ro/SSA, and RF were significantly
more common in the S3 group of patients (3, 4). Interestingly,
the difference in detected anti-La/SSB between patients with
moderate lesions and severe lesions was insignificantly
small (Table 1).
Inflammation grade has been reported to influence the shift of
infiltrating immune cell populations within the MSG, however,
the changes are not extensively described and there appears to be
a lack of consistency in the available data. This could be
explained by methodological variations ascribed to evaluating
the cell occurrence (e.g., cells per randomly selected tissue-area,
number of cells in infiltrates), the grading system for
inflammation (e.g., focus score, Tarpley score, Chisholm
score), and the patient stratification (e.g., based on different
histological or clinical features). In the current study, the stained
immune cells were quantified within the focal infiltrates, which
are hallmark features in the pSS biopsies that can be used to
describe inflammatory disease severity and should follow certain
criteria with respect to the infiltrate’s cellular quantity and its
surrounding tissue, in agreement with the recommendations by
Fisher et al. (21). To allow for a broader understanding of the
early biological changes that contribute to disease initiation,July 2021 | Volume 12 | Article 701581




FIGURE 3 | Immunohistochemical detection and quantification of CD4+ Th cells in the MSG of pSS patients. CD4+ Th cells were most frequently observed in the
focal infiltrates of MSG across all inflammatory severity stages (A–F) and dropped significantly in S2 compared to S1 (p = 0.009), in addition to S2 compared to S1
and S3 combined (p = 0.011) as determined by Student's T test (G). Immunohistochemical staining displaying the distribution of a specific immune cell in three
representative examples of focal infiltrates in the MSG as classified into the respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3 (E, F). Image (B) is
a magnification of (A), image (D) is a magnification of (C), image (F) is a magnification of (E). Scale bar = 0.5 mm. Bars (G) indicate the mean percentage of cell-type
number/total infiltrating mononuclear cells in each stage and error bars represent ± SEM. Statistical significance is notated: * = p < 0.05, ** = p ≤ 0.01. The Student's
T test was applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 7015818




FIGURE 4 | Visualization of CD8+ Tc cells in the MSG of pSS patients. CD8+ cells were observed in both periductal foci and within the epithelial lining of salivary
ducts, where such ducts mostly appeared to be non-dilated (A–F). Interestingly, the incidence of CD8+ cells fluctuated largely between patients regardless of lesion
severity (G). Immunohistochemical staining displaying the distribution of a specific immune cell in three representative examples of focal infiltrates in the MSG as
classified into the respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3 (E, F). Image (B) is a magnification of (A), image (D) is a magnification of
(C), image (F) is a magnification of (E). Scale bar = 0.5 mm. Bars (G) indicate the mean percentage of cell-type number/total infiltrating mononuclear cells in each
stage and error bars represent ± SEM. The Student's T test was applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 7015819




FIGURE 5 | Identification of FoxP3+ cells in the MSG of patients with pSS. Here, some of the detected FoxP3+ Tregs are indicated by arrows (A–F). FoxP3+ cells were
scarce or absent in the patients, particularly in the S2 group. Although the alternations in FoxP3+ cell-incidence in accord with inflammatory disease severity resembled
that of CD4+ Th cells, no significant differences were noted for this subpopulation (G). Immunohistochemical staining displaying the distribution of a specific immune cell in
three representative examples of focal infiltrates in the MSG as classified into the respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3 (E, F). Image (B)
is a magnification of (A), image (D) is a magnification of (C), image (F) is a magnification of (E). Scale bar = 0.5 mm. Bars (G) indicate the mean percentage of cell-type
number/total infiltrating mononuclear cells in each stage and error bars represent ± SEM. The Student's T test was applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 70158110




FIGURE 6 | Distribution of CD74+ cells in the MSG of patients with pSS. CD74+ APCs were found to predominantly accumulate within the inflammatory lesions
(A–F), and steadily increased in parallel with higher lesion severity (G). Immunohistochemical staining displaying the distribution of a specific immune cell in three
representative examples of focal infiltrates in the MSG as classified into the respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3 (E, F). Image (B) is
a magnification of (A), image (D) is a magnification of (C), image (F) is a magnification of (E). Scale bar = 0.5 mm. Bars (G) indicate the mean percentage of cell-type
number/total infiltrating mononuclear cells in each stage and error bars represent ± SEM. The Student's T test and Mann–Whitney U test were applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 70158111




FIGURE 7 | Presence of CD68+ cells in the MSG of patients with pSS. The black arrows indicate detected CD68+ macrophages. The cells appeared co-localized
and morphologically larger inside the heavier focal infiltrates of S3 patients (A–F), yet the highest percentage of cells was detected in S1 lesions.
Immunohistochemical staining displaying the distribution of a specific immune cell in three representative examples of focal infiltrates in the MSG as classified into the
respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3 (E, F). Image (B) is a magnification of (A), image (D) is a magnification of (C), image (F) is a
magnification of (E). Scale bar = 0.5 mm. Bars (G) indicate the mean percentage of cell-type number/total infiltrating mononuclear cells in each stage and error bars
represent ± SEM. The Mann–Whitney U test was applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 70158112




FIGURE 8 | Distribution of CD20+ B cells and CD138+ plasma cells in the MSG of pSS patients. CD20+ B cells (magenta) were mostly observed in large numbers
within large focal infiltrates and GC, in contrast to CD138+ plasma cells (brown) which were localized throughout the glandular tissue. However, the double staining
revealed that both cell-types were commonly found adjacent to adipocytes (A–F), unlike the other mononuclear cells in this study. CD20+ B cells significantly
increased from S1 to S3 (p = 0.004) as tested by the Student's T test, from S2 to S3 (p = 0.004) as tested by the Mann–Whitney U test and were elevated in S3
compared to S1 and S2 combined (p < 0.001) as tested by the Student's T test. On the other hand, a higher incidence of CD138+ plasma cells in S1 and S2 lesions
together was discovered compared to S3 using the Mann–Whitney U test (p = 0.028). Immunohistochemical staining displaying the distribution of a specific immune
cell in three representative examples of focal infiltrates in the MSG as classified into the respective inflammatory severity stages; S1 (A, B), S2 (C, D), and S3
(E, F). Image (B) is a magnification of (A), image (D) is a magnification of (C), image (F) is a magnification of (E). Scale bar = 0.5 mm. Bars (G, H) indicate the mean
percentage of cell-type number/total infiltrating mononuclear cells in each stage and error bars represent ± SEM. Statistical significance is notated: * = p < 0.05,
** = p ≤0.01. The Student's T test and Mann–Whitney U test were applied.Frontiers in Immunology | www.frontiersin.org July 2021 | Volume 12 | Article 70158113
Bharaj et al. Immune Cell Alterations in pSSpSS patients with FS 0 and FS <1 were enrolled, as has been
recommended in previous studies (1, 28). Since several reports
have emphasized differences in disease activity status and
cytokine profiles between GC+ and GC− pSS patients, they
were separated by using the CD21 marker in addition to the
H&E evaluation for detection of follicular dendritic cell networks
present within the ectopic GC structures (19, 29).
The focal infiltrates were found to mainly comprise CD74+
cells, CD4+, and CD20+ cells. The CD20+ cells clearly
outnumbered the other CD74-expressing APCs; DCs, B cells,
and macrophages. The anti-human CD74 recognizes the MHC
class II invariant chain which is crucial for the formation,
transportation, and function of the MHC class II molecule
following antigen-binding. Additionally, the CD74 pathway
plays a crucial role in B cell survival and has been described as
complementary to that of the B cell receptor (BCR) and the B cell
activating factor receptor (BAFFR) (30). Interestingly, CD20+ B
cells comprised approximately half of the CD74+ APCs localized
within the mild and moderate inflammatory lesions, respectively,
and accounted for the vast majority of CD74+ APCs in the severe
lesions. Moreover, the number of these B cells was further
increased in severe lesions.
Besides recognizing antigens presented by APCs through the
class II MHC molecules, CD4+ Th cells express the CD74 ligand
macrophage migration inhibitory factor (MIF) and are key
players in promoting B cell survival signaling pathways, for
example through the activation of nuclear factor-kappa-B (NF-kB)
pathway, resulting in the transcription of anti-apoptotic genes in
these cells (30). In line with previous reports, it was observed that
CD4+ Th cells dominated over the CD8+ Tc cells, particularly at
earlier timepoints of the inflammatory course (15, 28, 31). One of
the most extensively studied CD4+ Th cells that gain access into
the GC are the T follicular helper (Tfh) cells which are up-
regulated in the salivary glands of pSS patients (32, 33), and have
been directly linked to support differentiation of antigen-specific
B cells into memory B cells and plasma cells at these sites (34). In
the present study, CD4+ Th cells were found to largely
accumulate in S3 patients comparatively to patients with a
higher focus score and absence of GC. However, as a
significant difference was not detected, further exploration to
uncover the suggested shift in the CD4+ Th cell subpopulations
could provide a better understanding of the development of these
intricate structures in the target tissue.
In contrast to the B cells from which they differentiate, CD138+
plasma cells in the focal infiltrates significantly declined in theMSG
of S3 patients. According to a study from 2011 by our group where
MSG biopsies from pSS patients were classified into FS = 1 and FS
≥2 irrespective of GC, there was an insignificant difference in
detected CD138+ plasma cells in the focal infiltrates between the
two groups,meanwhile, a significant increase in interstitial CD138+
plasma cells of biopsies with FS≥2 was reported when compared to
the other FS = 1 group (20). In this context, the plasma cells could
possiblybe elevated in theMSGofS3patients but rather accumulate
interstitially and form clusters or “infiltrates” of their own. This is
further supported by the GC and over-expressed plasma cell
survival factors, including CXCL12 and IL-6, which are releasedFrontiers in Immunology | www.frontiersin.org 14by epithelial cells, mononuclear cells, and adipocytes in the salivary
glands of pSS patients (14, 20). Arguably, this may to some extent
justify the preferred localization of plasma cells adjacent to
adipocytes in the interstitium as demonstrated in the current
study (Figures 8A–F), and in accordance with previous reports
(14, 20). Nevertheless, further data is required to elucidate
this concept.
Meanwhile, CD68+ macrophages and FoxP3+ Tregs
constituted the least common of all cell types investigated
within the focal infiltrates. As might be anticipated given that
both cells express the CD4 co-receptor, the percentages of both
CD68+ macrophages and FoxP3+ Tregs detected within the focal
infiltrates appeared to fluctuate insignificantly over the course of
the inflammatory progression in a relatively similar fashion to
CD4+ Th cells. Although the highest incidence of CD68+
macrophages were immunolocalized in the severe lesions (35),
the detected rise in cells associated with the mild lesions could
indicate an active role in orchestrating tissue injury as part of the
initial, innate immune response which could, in turn, possibly be
linked to the following increase in atrophy in the S2 group
(Table 1). Similar to the CD68+ macrophages, the FoxP3+ cells
were reduced in the moderate lesions, although differences were
insignificant. On the other hand, these cells have been found to
increase with higher salivary gland infiltration grade (36).
Interestingly, we did identify the highest cell incidence in the
S1 patients’ mild inflammatory lesions, probably reflecting the
immune system’s attempt to efficiently control local immune
responses in these patients following disease progression.
In summary, our findings provide novel insights into the pSS
disease pathogenesis, specifically by investigating the significance of
the salivary gland degradation which is usually coupled with
adipose tissue occurrence and immune cell alternations in the
focal infiltrates, and how they associate with clinical outcomes.
This could add valuable knowledge to the current understanding of
the disease pathogenesis and be directly transferred to the
optimization of available diagnostic strategies applied for pSS
patients in distinct inflammatory disease severity stages. Further
assessments of atrophy and adipose tissue in the context of
immunopathological cell aberrations in the salivary glands should
be encouraged, for example by imaging modalities and
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